Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.

Journal

Journal of Clinical Oncology

Series/Report No.

Journal of Clinical Oncology

Journal Volume

42

Start Page

482

End Page

482

Date Issued

2024-01-20

Author(s)

Finn R.S.

Kudo, Masatoshi

Merle, Philippe

Meyer, Tim

Qin, Shukui

Ikeda, Masafumi

Xu, Ruocai

Edeline, Julien

Ryoo, Baek-Yeol

Ren, Zhenggang

Galle, Peter R.

Kaneko, Shuichi

Kumada, Hiromitsu

Wang, Anran

Mody, Kalgi

Dubrovsky, Leonid

Siegel, Abby B.

Llovet, Josep M

URI

Type

review article